Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Skin Neoplasms 1Recurrence 1Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Glioblastoma 1Carcinoma, Basal Cell 1

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 108Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Dimethyl Fumarate × Clear all
NCT02784834 2019-09-19

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

University of California, San Diego

Phase 1 Terminated
2 enrolled 5 charts
LymphoidOther hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡